Ticker

Analyst Price Targets — OLN

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
April 10, 2026 12:26 pmRBC Capital$30.00$28.91TheFly Olin price target raised to $30 from $21 at RBC Capital
April 9, 2026 12:21 pmUBS$29.00$28.40TheFly Olin price target raised to $29 from $21 at UBS
February 17, 2026 12:05 pmEldain RodriguezMizuho Securities$24.00$25.88TheFly Olin price target raised to $24 from $22 at Mizuho
February 10, 2026 3:37 pmDeutsche Bank$26.00$25.88TheFly Olin price target raised to $26 from $23 at Deutsche Bank
February 3, 2026 12:25 pmBMO Capital$24.00$22.17TheFly Olin price target lowered to $24 from $25 at BMO Capital
February 2, 2026 9:02 pmDuffy FischerGoldman Sachs$22.00$22.17StreetInsider Goldman Sachs Reiterates Neutral Rating on Oiln (OLN)
February 2, 2026 3:08 pmPeter OsterlandTruist Financial$20.00$21.92TheFly Olin price target lowered to $20 from $23 at Truist
February 2, 2026 1:48 pmUBS$21.00$21.19TheFly Olin price target lowered to $21 from $22 at UBS
February 2, 2026 1:40 pmRBC Capital$21.00$20.96TheFly Olin price target lowered to $21 from $24 at RBC Capital
February 2, 2026 1:32 pmMorgan Stanley$18.00$20.97TheFly Olin price target lowered to $18 from $20 at Morgan Stanley

Latest News for OLN

Olin: Improving Margins By Factoring Cost Savings

Olin is expected to implement one of its largest cost-saving goals this year, estimated to be between $100 and $120 million. Given that we are starting to see top line recovery, mainly driven by the epoxy segment, cost savings will bring margin expansion. Momentum, growth, and profitability metrics are improving well and are superior to its peers, but the valuation remains depressed with an upside potential of 68%…

Seeking Alpha • Apr 7, 2026
Olin: Results May Be Bottoming

Olin remains a buy as Middle East conflict tightens global petrochemical supply, supporting US-centric producers and improving pricing power. OLN's Q1 likely marks the bottom, with Q2 expected to benefit from lower US natural gas prices and improved margins, especially in Chlor Alkali. Despite weak construction demand, supply disruptions and cost tailwinds should drive at least $150M free cash flow in 2026, with…

Seeking Alpha • Apr 5, 2026
Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN324 achieves faster, greater, and more durable reductions in wAMD pigment epithelial detachment (PED) thickness versus faricimab Ollin and Innovent Biologics adva ncing OLN324…

PRNewsWire • Mar 30, 2026
SG Americas Securities LLC Grows Stock Position in Olin Corporation $OLN

SG Americas Securities LLC raised its position in Olin Corporation (NYSE: OLN) by 142.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 455,757 shares of the specialty chemicals company's stock after acquiring an additional 267,458 shares during the quarter.

Defense World • Mar 30, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

Senate Trading Disclosures

NameTransaction DateTypeAssetAmountLink

No House trades found for OLN.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top